BioSyent BIOYF Stock
BioSyent Price Chart
BioSyent BIOYF Financial and Trading Overview
| BioSyent stock price | 12.21 USD |
| Previous Close | 12.03 USD |
| Open | 12 USD |
| Bid | 12.17 USD x 30000 |
| Ask | 12.24 USD x 90000 |
| Day's Range | 12 - 12.03 USD |
| 52 Week Range | 7.63 - 12.45 USD |
| Volume | 1.12K USD |
| Avg. Volume | 1.58K USD |
| Market Cap | 135.12M USD |
| Beta (5Y Monthly) | 0.594 |
| PE Ratio (TTM) | 19.403225 |
| EPS (TTM) | 0.62 USD |
| Forward Dividend & Yield | 0.16 (1.32%) |
| Ex-Dividend Date | August 31, 2026 |
| 1y Target Est | N/A |
BIOYF Valuation Measures
| Enterprise Value | 130.24M USD |
| Trailing P/E | 19.403225 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.427046 |
| Price/Book (mrq) | 4.1796556 |
| Enterprise Value/Revenue | 2.339 |
| Enterprise Value/EBITDA | 8.751 |
Trading Information
BioSyent Stock Price History
| Beta (5Y Monthly) | 0.594 |
| 52-Week Change | 53.44% |
| S&P500 52-Week Change | 12.86% |
| 52 Week High | 12.45 USD |
| 52 Week Low | 7.63 USD |
| 50-Day Moving Average | 11.6 USD |
| 200-Day Moving Average | 10.76 USD |
BIOYF Share Statistics
| Avg. Volume (3 month) | 1.58K USD |
| Avg. Daily Volume (10-Days) | 1.54K USD |
| Shares Outstanding | 11.23M |
| Float | 9.14M |
| Short Ratio | N/A |
| % Held by Insiders | 34.94% |
| % Held by Institutions | 4.17% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.21 |
| Trailing Annual Dividend Yield | 1.74% |
| 5 Year Average Dividend Yield | 141.00% |
| Payout Ratio | 0.2459 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 17.72% |
| Operating Margin (ttm) | 20.60% |
| Gross Margin | 73.37% |
| EBITDA Margin | 26.73% |
Management Effectiveness
| Return on Assets (ttm) | 15.89% |
| Return on Equity (ttm) | 23.65% |
Income Statement
| Revenue (ttm) | 55.67M USD |
| Revenue Per Share (ttm) | 4.92 USD |
| Quarterly Revenue Growth (yoy) | 95.19% |
| Gross Profit (ttm) | 40.85M USD |
| EBITDA | 14.88M USD |
| Net Income Avi to Common (ttm) | 9.87M USD |
| Diluted EPS (ttm) | 0.62 |
| Quarterly Earnings Growth (yoy) | 41.19% |
Balance Sheet
| Total Cash (mrq) | 8.94M USD |
| Total Cash Per Share (mrq) | 0.79 USD |
| Total Debt (mrq) | 3.14M USD |
| Total Debt/Equity (mrq) | 6.85 USD |
| Current Ratio (mrq) | 2.068 |
| Book Value Per Share (mrq) | 2.8782275 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 11.5M USD |
| Levered Free Cash Flow (ttm) | 7.59M USD |
Profile of BioSyent
| Country | United States |
| State | ON |
| City | Mississauga |
| Address | 2476 Argentia Road |
| ZIP | L5N 6M1 |
| Phone | 905-206-0013 |
| Website | https://www.biosyent.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Q&A For BioSyent Stock
What is a current BIOYF stock price?
BioSyent BIOYF stock price today per share is 12.21 USD.
How to purchase BioSyent stock?
You can buy BIOYF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioSyent?
The stock symbol or ticker of BioSyent is BIOYF.
Which industry does the BioSyent company belong to?
The BioSyent industry is Drug Manufacturers - Specialty & Generic.
How many shares does BioSyent have in circulation?
The max supply of BioSyent shares is 11.23M.
What is BioSyent Price to Earnings Ratio (PE Ratio)?
BioSyent PE Ratio is 19.69354800 now.
What was BioSyent earnings per share over the trailing 12 months (TTM)?
BioSyent EPS is 0.62 USD over the trailing 12 months.
Which sector does the BioSyent company belong to?
The BioSyent sector is Healthcare.
